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Background: Evaluation of patients who present to the hospital with acute undifferentiated chest pain or other symptoms 
and signs suggestive of Acute Coronary Syndrome (ACS) is often a clinical challenge.
The initial assessment, requiring a focused history (including risk factors analysis), a physical examination, an electrocar-
diogram (EKG) and serum cardiac marker determination, is time-consuming and troublesome. Recent investigations have 
indicated that increases in biomarkers of necrosis, inﬂ  ammation, ischemia and myocardial stretch may provide earlier 
assessment of overall patient risk, help in identifying the adequate diagnostic and therapeutic management for each patient 
and allow for prevention of substantial numbers of new events.
Approach and Content: The purpose of this review is to provide an overview of the characteristics of several biomarkers 
that may have potential clinical utility to identify ACS patients. Patho-physiology, analytical and clinical characteristics 
have been evaluated for each marker, underlying the properties for potential routine clinical use.
Summary: The biomarkers discussed in this review are promising and might lead to improved diagnosis and risk stratiﬁ  ca-
tion of patients with ACS, however their clinical application requires further studies. It is important to deﬁ  ne their clinical 
role as diagnostic markers, their predictive value and the speciﬁ  city, standardization and detection limits of the assays.
Introduction
The term “acute coronary syndrome” (ACS) encompasses a range of thrombotic coronary artery diseases, 
including unstable angina (UA) and both ST-segment elevation (STEMI) and non-ST-segment elevation 
myocardial infarction (NSTEMI).
Current estimates are that 1.7 million patients with ACS are admitted each year to hospitals in the 
United States (American Heart Association: 2004 Heart and Stroke Statistical Update). Of these, only 
one-quarter present with STEMI; three quarter, or approximately 1.4 million patients, have UA or 
NSTEMI. It’s further estimated that 4% of patients admitted to the Emergency Department (ED) with 
Acute Myocardial Infarction (AMI) have an inadequate discharge with considerable risk of cardiac 
events at home for patients (Lee TH et al. 1987).
It is evident that the epidemiological importance of the phenomenon, the potentially lethal 
consequences for the patient, and the economical and legal implications for clinicians make the need 
of an adequate strategy of diagnostic and therapeutic management, including risk stratiﬁ  cation and 
prevention of possible new events.
However, the deﬁ  nition of the assessment protocol in the evaluation of patients with chest pain or 
other symptoms suspected for ACS is difﬁ  cult. ACS requires early identiﬁ  cation, adequate risk strati-
ﬁ  cation and management: patients with ongoing chest pain and persistent ST-segment elevation (or 
new-onset left bundle branch block) require immediately recanalization by ﬁ  brinolytic treatment or 
primary angioplasty in patients with chest pain and EKG abnormalities suggesting acute ischemic heart 
disease, the strategy is to value the likelihood of ACS and to conﬁ  rm or rule out myocardial necrosis, 
to alleviate ischemia and symptoms, to observe with serial EKG, to repeat measurements of markers 
of myocardial necrosis and to initiate appropriate therapy. However, suggested approach consistent of 
history, EKG and serum cardiac markers determination is time-consuming and not necessarily accurate: 
clinical presentation of ACS is often atypical, EKG abnormalities are not always present (Pope JH et al. 
1998) and markers of myocardial necrosis may be negative at admission.
Recent investigations have indicated that increases in several biomarkers upstream may provide 
earlier assessment of overall patient risk, help in identifying the adequate diagnostic and therapeutic 454
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management for each patient and allow for 
prevention of cardiac new events. It is now appar-
ent that ACS shares a common anatomical sub-
strate: pathological, angioscopic and biological 
observations have demonstrated that UA and acute 
myocardial infarction (AMI) are different clinical 
presentations that result from a common underly-
ing patho-physiological mechanism, namely 
atherosclerotic plaque rupture or erosion, with dif-
ferent degrees of superimposed thrombosis and 
distal embolization (Davies MJ et al. 1993; 
Davies M, 1995; Davies M, 1997).
Traditional Markers of Myocardial 
Damage
Creatine kinase (CK) and creatine 
kinase-MB (CK-MB)
Creatine kinase (CK) and creatine kinase-MB 
(CK-MB) have a long history as the gold standard 
for AMI diagnosis. CK-MB is a CK isoenzyme, 
predominantly found in the myocardium. Its eleva-
tion occurs 4–6 h after the onset of myocardial 
necrosis and remains for 24–48 h. CK-MB sensi-
tivity and speciﬁ  city in detecting myocardial injury 
can be increased by serial testing (Gibler WB et al. 
1990). CK-MB is relatively sensitive, but its spec-
iﬁ  city is affected by the presence of this marker in 
skeletal muscle. Elevation in CK-MB, in fact, may 
occur as a result of occasional analytical interfer-
ences and in patients with trauma, rabdomyolysis, 
myopathies, renal failure or during the peripartum 
period. To improve its speciﬁ  city, it was proposed 
to use CK-MB relative index (CK-MB/total CK). 
Ratios greater than 2.5 percent are considered sug-
gestive of myocardial damage (Pearson JR et al. 
1990). Mass assays for CK-MB have largely 
replaced older activity assays based on electropho-
resis, and because of their better analytical sensitiv-
ity and precision. CK-MB activity assay were and 
are limited by their inability in detecting 
low concentrations of CK-MB. In addition, 
electrophoresis and column chromatography meth-
ods were subject to false-positive interference from 
so-called macro-CK, caused by an immune 
response against CK-MB in some populations. For 
these reasons, CK-MB activity assays gave away 
to more analytically sensitive and speciﬁ  c mass 
immunoassays that offered the advantage of 
quantifying CK-MB as a speciﬁ  c protein, rather 
than relying on functional enzymatic activity as a 
surrogate. CK-MB mass, CK-MB activity and total 
CK are more speciﬁ  c than myoglobin, but may not 
be detectable for 4–6 h in the bloodstream following 
myocardial injury. The sensitivity of CK-MB mass 
for AMI is only 50% when measured early at the 
time of presentation (Bertrand ME et al. 2002). 
In clinical practice, peak levels of markers of 
necrosis and area under the time release curve of 
CK-MB from repetitive serial samplings are used 
to estimate infarct size.
Cardiac troponin T (cTnT)
and I (cTnI)
Cardiac troponin T (cTnT) and cardiac troponin 
I (cTnI) are more sensitive and speciﬁ  c markers 
than CK-MB in detecting myocardial necrosis, 
and have become the preferred biomarkers for 
the diagnosis of AMI. They are also a useful 
prognostic indicator in patients with ACS. The 
superior clinical performance of troponin results 
from its higher sensitivity for smaller myocardial 
injury and its virtually total specificity for 
cardiac damage (Jaffe AS et al. 2000) and is 
considered the gold-standard in the new deﬁ  nition 
of myocardial infarction (Thygesen et al. 2007). 
Troponin is a complex of three proteins that is 
integral to muscle contraction in skeletal and 
cardiac muscle, regulating the calcium-mediated 
interaction between actin and myosin. Its three 
subunits are TnC, TnI, and TnT. Troponin C binds 
to calcium ions in order to produce movement; 
Troponin T binds to tropomyosin, interlocking 
it to form a troponin-tropomyosin complex; Tro-
ponin I binds to actin in thin myoﬁ  laments to 
hold the troponin-tropomyosin complex in place. 
When calcium is bound to speciﬁ  c sites on TnC, 
the structure of the thin ﬁ  lament changes in such 
a manner that myosin (a molecular motor orga-
nized in muscle thick ﬁ  laments) attaches to thin 
ﬁ  laments and produces force and/or movement 
(Gillis TE et al. 2007). In the absence of calcium, 
tropomyosin interferes with action of myosin, 
and therefore muscles remain relaxed. Troponin 
C has an identical amino-acid sequence in both 
skeletal and cardiac tissues and, thus, it has no 
potential as a cardiac speciﬁ  c marker. However 
Troponin T and Troponin I have different 
isoforms in cardiac and skeletal muscle, encoded 
by separated genes, and consequently, have 
different amino-acid sequences (Christenson RH 455
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and Azzazy HME, 1998). The respective cardiac 
isoforms of TnT (cTnT) and TnI (cTnI) allow 
production of antibodies that exclusively recog-
nize these myocardial-speciﬁ  c proteins. To date, 
cTnT and cTnI release has not been attributed to 
a tissue source other than myocardium, and 
except for rare analytical false positives, 
detection of cTnT or cTnI in the blood is indica-
tive of heart injury (Jaffe AS, 2001). Serial 
measurements of cardiac troponin signiﬁ  cantly 
improve the ability of this biomarker in detecting 
AMI (REACTT Investigators study group 1997). 
Hamm et al. (Hamm et al. 1997) performed tro-
ponin testing upon presentation and at 4 h with 
improvement in the sensitivity from 51% to 94% 
for cTnT and 66% to 100% for cTnI in patients 
without ST-elevation. Higher diagnostic sensitiv-
ity and speciﬁ  city require specimen collection at 
patient presentation, 6–9 h later and at 12–24 h 
if clinical suspicion is high and earlier results are 
negative. Indeed, troponin is not considered as 
an early biomarker of myocardial necrosis: car-
diac troponins need 4–10 h after symptoms onset 
to appear in serum, and peak at 12–48 h, remain-
ing then abnormal for several days to two weeks 
(Panteghini M et al. 1999). However, troponins 
can help to identify such patients at high risk of 
infarction and death for whom earlier and more 
invasive investigation is indicated. Increase in 
troponin levels represents a powerful marker of 
high short-term risk of death or nonfatal myo-
cardial infarction in patients with non-ST-eleva-
tion acute coronary syndromes (NSTE-ACS); it 
is one of the indicators for an early invasive 
strategy, according to American College of Car-
diology/American Heart Association guidelines 
(ACC/AHA) (Anderson JF et al. 2007). There is 
also a relationship between the severity of the 
infarct and the duration of the elevated serum 
cardiac troponins. The release periods of troponin 
in patients with NSTEMI are signiﬁ  cantly less 
than those with ST-elevation at EKG, and tropo-
nin elevations in traditionally deﬁ  ned unstable 
angina patients, representing microscopic infarct, 
might last only several hours at a time (Panteghini 
et al. 2002).There is substantial evidence that 
30% of patients with unstable angina have cir-
culating troponins, indicating a subset of patients 
with cell damage (Collinson PO et al. 1996). 
When troponin elevations occurred without 
elevation of CK or CK-MB, patients were often 
classiﬁ  ed as having ‘‘minor myocardial dam-
age’’, yet they have increased subsequent fre-
quencies of death, myocardial infarction and 
need for revascularization (Ohman EM et al. 
1996; Olatidoye, 1998) and therefore are now 
considered as myocardial infarction. From a 
clinical perspective, there is evidence that any 
amount of detectable cardiac troponin release is 
associated with an increased risk of new adverse 
cardiac events (Kavsak et al. 2007). The new 
global definition of myocardial infarction 
receives and organizes these observations deﬁ  n-
ing any amount of cardiac troponin  99th per-
centile (10% Coefﬁ  cient of Variation method) as 
myocardial infarction. Haft and colleagues (Haft 
JI and Saadeh SA, 1997) reported that patients 
with elevated troponin values tend to have a high 
incidence of complex lesions and that these 
lesions tend to be of very high grade. In contrast, 
individuals without elevations of troponin are 
less likely to have complex lesions and in general 
have lesions that are less severe in terms of the 
percentage of obstruction. The role of troponins 
as a tool for identiﬁ  cation of patients at high risk 
is of interest also for therapeutic management. 
In a retrospective analysis, Hamm (Hamm CW 
et al. 1999) segregated patients in two groups by 
the presence or absence of increased plasmatic 
levels of cTnT and demonstrated that only indi-
viduals with increased levels of cTnT beneﬁ  t 
from abciximab therapy, with substantially 
reduced events rate both at 30 days and at 6 
months. In contrast, in the group without eleva-
tions of cTnT, abciximab had no statistically 
signiﬁ  cant effect on event rates. Thus, evaluation 
of troponin values may provide a strategy for the 
therapeutic subsetting of patients with unstable 
angina and those in need of angioplasty proce-
dures who may be at risk for complications. It 
appears that patients with elevations of 
the troponins may require more aggressive 
anticoagulant/antithrombotic therapy than those 
with normal values (Lindahl B et al. 1997).
These data demonstrate that troponin is a 
powerful marker for the hallmark of AMI and a 
useful tool in assessing risk and directing appropriate 
therapy that improves clinical outcome. Although 
cardiac troponins are speciﬁ  c of cardiac damage, 
they cannot be considered as the deﬁ  nitive marker 
of myocardial ischemic injury. Troponin release 
occurs due to non-ischemic cardiac damage, too, 
causing “false positive” elevations: myopericarditis, 
aortic dissection, aortic valve disease, hypertrophic 456
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cardiomyopathy, cardiac contusion or other trauma, 
tachy- or bradyarrhytmias, apical ballooning syn-
drome, congestive heart failure. Furthermore, 
elevation of cardiac troponin can also occur in non 
primary cardiac pathologies, such as acute 
neurological diseases, including stroke or sub-
arachnoid hemmorrhage, inﬁ  ltrative diseases, drug 
toxicity or toxins, burns affecting  30% of body 
surface area (Thygesen K et al. 2007). An other 
important clinical challenge is the signiﬁ  cance of 
elevated concentrations of cTnT commonly found 
in patients with renal failure but no clinical signs 
of recent myocardial damage (Freda BJ et al. 
2002); even in this setting, however, raised levels 
of troponin are associated with adverse cardiac 
prognosis.
There are a few methodological problems, in 
particular the lack of standardisation of assays for 
cTnI. Plasma levels of cTnI are associated with 
cardiac morbidity and mortality and have an inde-
pendent prognostic value in patients with ACS 
(Galvani M et al. 1997) but there is no consensus 
on common reference values and standardization 
between the several commercially available cTnI 
assays. More than 15 companies presently market 
assays for cTnI employing different standard mate-
rials and antibodies with different epitope speci-
ficities. Consequently, different results from 
different cTnI systems and assay generations may 
be obtained and this problem may cloud the inter-
pretations of reported data, creating a substantial 
problem for the clinical and laboratory communi-
ties (Apple FS, 1999).
B-type natriuretic peptide (BNP)
B-type natriuretic peptide (BNP) is preferentially 
produced and secreted in the left ventricle, although 
the right side of the human heart also synthesises 
and secretes BNP in response to disease (Kay JD 
et al. 2003). The predominant stimulus controlling 
the synthesis and release of BNP from cardiac atria 
and ventricles is wall stretch. BNP expression and 
release from cardiomyocites can also be stimulated 
by a variety of endocrine, paracrine and autocrine 
factors that are activated in heart failure, including 
norepinephrine, angiotensin II, ET-1, glucocorticoids 
and proinﬂ  ammatory cytokines. In general, the 
plasma concentrations of these peptides are 
increased in diseases characterised by an expanded 
fluid volume, such as renal failure, primary 
aldosteronism and congestive heart failure (CHF), 
or by stimulation of peptide production caused by 
ventricular hypertrophy or strain, thyroid disease, 
excessive circulating glucocorticoids or hypoxia 
(Clerico A et al. 1999). Natriuretic peptides inhibit 
renin-angiotensin-aldosterone axis, increasing 
diuresis and reducing ventricular preload and arte-
rial blood pressure, and inhibit central sympathetic 
outﬂ  ow and catecholamine release from peripheral 
sympathetic neurons.
Available Commercial immunoassays measure 
BNP and its N-terminal inactive form NT-proBNP. 
The half-life of BNP is 20 min whereas NT-proBNP 
has a half-life of 120 min (Kemperman H et al. 
2004), which explains why NT-proBNP serum 
values are approximately six times higher than 
BNP values, even though both molecules are 
released in equimolar proportions (Hall C, 
2005).
Because of the longest half-life NT-proBNP 
could be more sensitive than BNP in the diagnosis 
of the earliest phase of the left ventricular dysfunc-
tion (Hunt PJ et al. 1995). Many assays, including 
those for the promising Mid Terminal (MT) BNP 
are now under development. It has been shown in 
several studies that BNP and NT-proBNP are 
related to sex, with higher values in females, and 
to age, with higher values in older individuals. In 
patients with reduced renal function, BNP and 
NTproBNP values are increased with a negative 
correlation to creatinine clearance. Worsening renal 
function affects clearance of NT-proBNP greater 
than BNP (Weber M and Hamm C, 2006), however 
deFilippi et al. have recently shown that the diag-
nostic accuracies of BNP and NT-proBNP in 
detecting decompensated heart failure are similar 
in patients with or without renal failure and that 
NT-proBNP is superior to BNP in predicting 
mortality (deFilippi CR et al. 2007).
The clinical usefulness of cardiac natriuretic 
peptides (especially BNP and NT-proBNP) in the 
evaluation of patients with suspected heart failure, 
in prognostic stratiﬁ  cation of patients with CHF, in 
detecting LV systolic or diastolic dysfunction and 
in the differential diagnosis of dyspnoea was con-
ﬁ  rmed (Cowie MR et al. 2003). In general, heart 
failure is unlikely at BNP values  100 pg/ml and 
is very likely at BNP values  500 pg/ml and, 
similarly, unlikely at NT-proBNP values  300 pg/ml 
and very likely at NT-proBNP values  450 pg/ml 
( 900 pg/ml in patients above 50 years of age) 
(Kay JD et al. 2003). Independent of their diagnostic 
value, several large scale studies have convincingly 457
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shown that BNP and NT-proBNP provide strong 
prognostic information for an unfavourable out-
come (death, cardiovascular death, readmission or 
cardiac events) in patients with heart failure or 
asymptomatic left ventricular dysfunction. It was 
also shown that a decrease in BNP during the initial 
hospital stay was associated with a favourable 
clinical outcome, whereas no change or an increase 
in BNP values was associated with an unfavourable 
outcome (Struthers AD, 1999).
Although originally BNP and NT-proBNP were 
considered biomarkers for heart failure only, now 
they are also considered biomarkers of myocardial 
ischemia. Elevated BNP and NT-pro-BNP levels have 
been observed in patients with stable coronary artery 
disease (CAD), in patients with UA (Kikuta K et al. 
1996) and during and after Percutaneous coronary 
intervention (PCI) (Tateishi et al. 2000). From recent 
studies it has emerged that the long and short-term 
prognostic power of BNP and NT-proBNP is similar, 
in the acute myocardial infarction with ST-elevation 
and without ST-elevation, both at hospital admission 
and during hospitalization (Galvani et  al. 
2004). It is widely believed that the underlying 
patho-physiological process causing an increase in 
BNP and NT-proBNP values is left ventricular sys-
tolic or diastolic dysfunction caused by myocardial 
ischemia that leads to an increased wall stress. Nev-
ertheless, data derived from experimental studies 
suggest a direct release of BNP and NTproBNP from 
cardiomyocytes in response to myocardial ischemia 
independent of ventricular wall stress (Morita E et al. 
1993). In the early phase after AMI there is an 
augmented production of cardiac natriuretic peptides 
related to myocardial stretch secondary to LV dys-
function, to increased heart rate, hypoxia and isch-
emia per se. Recent studies suggest that the augmented 
release of BNP following brief periods of ischemia 
occurs without concomitant change in LV end dia-
stolic pressure, suggesting that ischemia per se is the 
stimulus for BNP release (D’Souza SP and Baxter 
GF, 2003). BNP and NT-pro-BNP have also emerged 
as prognostic indicators of long-term mortality early 
after an acute coronary event. This association was 
observed across the spectrum of ACS, including 
patients with STEMI, NSTEMI and UA, those with 
and without elevated cardiac troponins, and those 
with and without clinical evidence of heart failure (de 
Lemos JA and Morrow DA, 2002; White HD and 
French JK, 2003). Substudies of large scaled clinical 
trials (Varo N et al. 2003; Sabatine MS et al. 2002; 
Lindahl B et al. 2005; Jernberg T et al. 2004; 
Heeschen C et al. 2004) have evaluated the prognostic 
value of BNP and NT-proBNP in patients presenting 
with NSTE-ACS. In all studies elevated values of 
BNP and NT-proBNP have consistently been found. 
In a recent analysis made by the group of Sabatine 
(Sabatine et al. 2002) in 450 patients of the OPUS-TIMI 
14 and in 1635 patients of the TACTICS-TIMI18 
(de Lemos JA and Morrow DA, 2002) in which was 
investigated an approach with multiple markers in 
ACS without ST elevation, BNP, C-Reactive Protein 
(CRP) and cTnI were all independent predictors of 
adverse outcome (Sabatine et al. 2002). The incidence 
of the adverse events not only resulted correlated with 
the positivity of each marker but also with the number 
of positive markers. Although patients with the worse 
prognosis (with a relative risk of death to 30 days 
between 6.0 and 13.0) were those with combined 
increase of levels of cTnI (marker of thrombosis and 
myocardial necrosis), of CRP (expression of inﬂ  am-
matory status) and of BNP (marker of myocardial 
dysfunction). Similar results were reported for the 
predictive value of BNP and NT-proBNP after 
STEMI. Quite recently, plasma natriuretic peptide 
concentrations were also related to risk of cardiovas-
cular events and death in apparently asymptomatic 
persons (Wang TJ et al. 2004).
The therapeutic beneﬁ  ts that can derive from 
BNP and NT-proBNP assessment in ACS are not 
clear. In a substudy of the FRISC-II trial (Lindhal B 
et al. 2005) which investigated the usefulness 
of NT-proBNP for identifying patients who 
might beneﬁ  t from an early invasive strategy, a 
trend towards a better outcome of patients 
with NT-proBNP values in the highest tertile 
was observed. In the substudy of the PRISM 
trial, Heeschen et al. analysed the effect of 
glycoprotein IIb/IIIa inhibition with tirofiban 
with respect to NT-proBNP values (Heeschen 
et al. 1999). They found that patients with high 
NT-proBNP values had a lower event rate with 
tiroﬁ  ban treatment compared to placebo at 48 h, 
they found no significant interaction between 
NT-proBNP values and the clinical beneﬁ  t of tiro-
ﬁ  ban treatment at 30 days. Further studies are 
needed to assess the therapeutic beneﬁ  ts that can 
derive from BNP and NT-proBNP assessment. 
Recent data suggest that natriuretic peptides may 
help to better identify the very high risk patients 
and the very low risk ones among a population of 
ACS patients with respectively positive or negative 
troponin. The role of BNP and NT-proBNP testing 
is included in the guidelines for the diagnosis and 458
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treatment of chronic heart failure of the task force 
of the European Society of Cardiology, published 
in 2005. Assessment of both markers is considered 
to be a reliable rule-out test of heart failure in pri-
mary care and in the emergency room. Assessment 
of BNP for risk stratiﬁ  cation is also mentioned in 
the guidelines of the European Society of Cardiol-
ogy for management of acute coronary syndromes 
in patients presenting without persistent ST segment 
elevation, but without any recommendations for 
the application of BNP and NT-proBNP in clinical 
routine (Kay JD et al. 2003).
C-Reactive protein (CRP)
CRP is the most widely studied inflammation 
marker. CRP is a pentraxin, synthesized by liver 
after stimulation by cytokines, especially IL-6, 
IL-1β and TNF-α, in response to tissue injury or 
infection (Volanakis JE, 2001). CRP is an acute-phase 
protein and a marker of inﬂ  ammation, but has also 
an active role in the innate immune response: 1) it 
activates the classic complement system, 2) rules 
the expression of the endothelial NO synthetase 
and the synthesis of NO and 3) induces the expres-
sion of the molecules of adhesion and the activation 
of the NF-kB. Moreover, it can directly regulate 
the oxidation of the LDLs.
The advantages of CRP as an inﬂ  ammatory 
biomarker are related in part to analytic properties 
(such as the availability of low-cost, accurate 
high-sensitivity assay) and in part to its biological 
proﬁ  le, including a long half-life (19 h). Liuzzo 
et al. ( Liuzzo G et al. 1994) showed that patients 
presenting with unstable angina and elevated 
plasma concentrations of CRP had a higher rate of 
death, AMI and need for revascularization com-
pared with patients without elevated concentrations. 
In more recent trials, other investigators have 
conﬁ  rmed the increased risk associated with higher 
CRP concentrations (Morrow DA et al. 1998). In 
the majority but not in all the studies, CRP has been 
showed to be a marker of the short—term risk 
(in hospital or 30 days) of recurrent cardiac events, 
including, death, AMI, and urgent revascularization 
(Biasucci LM et al. 2000). More consistently CRP 
was found to be independently associated with the 
recurrence of cardiovascular events and with death 
in the mid to long term (Biasucci LM et al. 1999; 
Heeschen C, 2000). An incremental prognostic 
power of CRP along with Troponin has been clearly 
demonstrated (Rebuzzi AG et al. 1998; Morrow DA 
et al. 1998). This association is of similar magnitude 
to other major clinical predictors of complications 
in ACS, including age, ST-abnormalities and car-
diac troponin. In each of the above studies, the 
predictive value of CRP was independent of, and 
additive to, cardiac troponin. More importantly, 
CRP was found to have prognostic value even 
among patients with negative cardiac troponin and 
no evidence of myocyte necrosis (Lindahl B et al. 
2000). Therefore its prognostic relationship is not 
a merely consequence of the inﬂ  ammatory response 
to myocardial necrosis and is present in patients 
with no evidence of myocardial injury as detected 
by cardiac troponin (Liuzzo G et al. 1994), although 
the data were obtained with troponin assays not at 
high sensitivity.
A variety of cut-off points have been used in 
clinical studies of CRP in ACS, leaving some 
uncertainty about the optimal decision limits. In 
primary prevention studies the relationship is 
graded with a very low risk reported for CRP 
levels   1.0 mg/l, intermediate risk between 1 
and 3 and high risk above 3 mg/L (James SK et al. 
2003). Liuzzo et al. (Liuzzo et al. 1994) used a 
cut-off of 3 mg/l, based on the 90th percentile of 
a normal distribution. Dichotomized at this cut-off 
point, CRP identiﬁ  ed patients at increased risk of 
in-hospital recurrent ischemic events. Biasucci 
et al. observed that levels of CRP  3 mg/l at 
discharge distinguished those patients at higher 
risk of cardiovascular events. However the 
majority of studies with CRP assessed at entry for 
ACS have found 10 mg/L as an optimal cut-off 
point for future events, in particular death. Mueller 
et al. (Mueller et al. Circulation 2002) found that 
a serum CRP   10 mg/l was associated with a 
higher risk of death in patients with NSTE-ACS 
despite aggressive management with early inva-
sive therapy. More recently, Scirica et al. (Scirica 
BM et al. 2007) found that in patients with UA/
NSTEMI, CRP levels  3 mg/L were associated 
with increased 10-month mortality, whereas in 
STEMI a relationship with mortality was seen at 
CRP levels  10 mg/L and therefore they sug-
gested that CRP measurement should be per-
formed early after presentation and index 
diagnosis-speciﬁ  c cutpoints should be used. The 
American Heart Association /Centers for Disease 
Control and Prevention (AHA/CDC) have deﬁ  ned 
speciﬁ  c cut-off points for clinical interpretation: 
CRP concentrations  1 mg/l are considered low, 
1–3 mg/l are average and  3 mg/l indicate high 459
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relative risk (Pearson TA et al. 2003). A CRP 
concentration  10 mg/l appears to be the optimal 
cut-off point (when applied during hospitaliza-
tion) for prediction of new AMI and death in 
secondary prevention (James SK et al. 2003).
Available data support the use of CRP in 
conjunction with troponin and other traditional 
clinical tools as a prognostic marker in patients 
with ACS. Studies from Ridker’s group (Ridker 
PM et al. 2002) demonstrate that CRP may give 
important information above those predicted by 
cholesterol levels in subjects at intermediate risk. 
Data from PROVEIT-TIMI22 (Ridker PM et al. 
2005) have shown that optimal levels of LDL 
cholesterol don’t give optimal protection, unless 
CRP is also lowered below 2 mg/L. Accordingly, 
the AHA/CDC scientiﬁ  c statement on the use of 
markers of inﬂ  ammation in cardiovascular disease 
in clinical practise includes recommendation for 
the use of CRP to identify patients at higher 
absolute risk of recurrent cardiovascular events 
and candidates for more aggressive monitoring and 
therapy, although the results of such strategy are 
not established. However, because CRP is closely 
but not speciﬁ  cally related to the presence of the 
inﬂ  ammatory process underlying ACS, research 
activities have focused to the identiﬁ  cation of more 
speciﬁ  c markers of vascular inﬂ  ammation.
The relative and independent role of CRP in 
ACS in comparison to troponin and natriuretic 
peptides has been widely assessed and discussed. 
In 2003 Centre for Disease Control/American 
Heart Association (Pearson TA et al. 2003) 
disseminated a scientiﬁ  c statement on the use of 
CRP and other inflammatory markers, the 
consensus was that CRP may be useful to address 
and tailor intensive medical treatment after ACS, 
but that no deﬁ  nite evidence existed to suggest 
such strategy. More recently the National Academy 
of Clinical Biochemistry has published (NACB 
writing group 2007) the guidelines on clinical 
characteristics and Utilization of biochemical 
markers in ACS.
These guidelines consider cardiac troponin the 
best biomarker for initial evaluation and early risk 
stratiﬁ  cation of ACS (both class IA), conversely 
natriuretic peptides (BNP and NT-proBNP) and 
CRP are not considered in the initial evaluation 
and have a class IIA (level of evidence A) recom-
mendation for early risk stratiﬁ  cation in ACS in 
addition to cardiac troponin, while their use a sole 
marker is discouraged. These guidelines appear 
well balanced and based upon the strong evidence 
in favor of troponin and, conversely, the lack of 
consistent data in favor of a clinical strategy based 
on natriuretic peptides and CRP.
Marker of Plaque Destabilization 
and Rupture
Placental growth factor (PIGF)
Placental growth factor (PIGF), a member of the 
vascular endothelial growth factor (VEGF) family, 
was shown to be profoundly upregulated in early 
and advanced atherosclerotic lesions (Luttun A 
et al. 2002). PIGF is a 50 kDa platelet-derived 
protein consisting of 149 aminoacids. It exists in 
two forms, PIGF-1 and PIGF-2, differing only for 
an aminoacid. Originally identiﬁ  ed in the placenta 
(Maglione D et al. 1991), PIGF mRNA is expressed 
by various tissues, including thyroid and lung 
(Tjwa M et al. 2003). PIGF functions are incom-
pletely understood. It might have a role in the ﬁ  rst 
phases of the inﬂ  ammatory process through stim-
ulation of vascular smooth muscle growth, recruit-
ment of macrophages into atherosclerotic lesions, 
upregulation of tumor necrosis factor-α (TNF- α) 
and monocyte chemoattractant protein-1 produc-
tion by macrophages (Heeschen C et al. 2004). 
Besides, it enhances production of Tissue Fac-
tor and stimulates pathological angiogenesis 
(Autiero M et al. 2003). Interestingly, experimental 
PIGF inhibition, by blocking its receptor Flt-1, 
suppresses both atherosclerotic plaque growth and 
vulnerability via inhibition of inﬂ  ammatory cell 
inﬁ  ltration (Pearson TA et al. 2003). All these data 
suggest that PIGF may act as a primary inﬂ  amma-
tory instigator of atherosclerotic plaque instability 
and therefore, inhibition of its effects may represent 
a new therapeutic target.
In 2004 Heeschen et al. (Heeschen C et al. 2004) 
investigated the potential role of PIGF for assessing 
risk of death or non-fatal myocardial infarction in 
the 30 days after index presentation. They studied 
1173 patients divided into two cohorts: one having 
angiographically conﬁ  rmed ACS (n = 547 enrolled 
in the CAPTURE trial) and the other presenting to 
the Emergency Department (ED) with chest pain 
(n = 626 enrolled in Germany). In order to avoid the 
possibly confounding effect of antiplatelet therapy 
only patients of the CAPTURE placebo arm were 
included in the assessment of PIGF. In the 
CAPTURE cohort, 40.8% patients were found to 460
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have increased PIGF concentrations and were found 
to have a markedly increased risk of adverse events 
at 30 days; also in the other cohort, PIGF was a 
predictor of increase in risk. These data suggest that 
PIGF blood levels may represent a novel, powerful, 
independent, prognostic determinant of clinical 
outcome in patients with ACS. Intriguingly, elevated 
PIGF levels identiﬁ  ed not only patients with ACS 
presenting with acute chest pain, but also patients 
with an increased risk of recurrent instability after 
discharge. The predictive value of PIGF levels is 
independent of myocardial necrosis, as evidenced 
by elevated troponin levels (Heeschen C et al. 1999), 
as well as platelet activation, as evidenced by 
elevation of sCD40L (Heeschen C et al. 2003a).
In summary, although large trials are still needed 
to obtain PIGF validation and commercialization, 
it appears to have great potential as an independent 
biomarker for plaque disruption, ischemia and 
thrombosis and also as a novel anti-inﬂ  ammatory 
therapeutic target in patients with CAD.
Myeloperoxidase (MPO)
Myeloperoxidase (MPO) is a hemoprotein (molecular 
mass ∼140 kDa) composed of a pair of heavy and 
light chains. It is an enzyme that catalyzes the con-
version of chloride and hydrogen peroxide to hypo-
chlorite and has the optimum of activity at acid pH. 
It is stored in azurophilic granules of polymorpho-
nuclear neutrophils and macrophages and is released 
into extracellular ﬂ  uid in the setting of inﬂ  ammatory 
process. MPO catalyzes activation reaction of several 
lysosomial proteins released as proenzymes from 
granulocytes (Klebanoff   SJ, 1999) and has been 
implicated in the oxidation of lipids contained within 
Low Density Lipoprotein (LDL) (Holvoet P, 1998). 
In addition, MPO consumes endothelial-derived NO, 
thereby reducing NO bioavailability and impairing 
its vasodilatatory and antinﬂ  ammatory functions. 
Furthermore, MPO has been showed to activate 
metalloproteinases and promote destabilization and 
rupture of the atherosclerotic plaque surface. The 
observation that MPO is involved in oxidative stress 
and inﬂ  ammation has been a leading factor to study 
MPO as a possible marker of plaque instability. 
Oxidative stress and inﬂ  ammation play a pivotal role 
in the pathogenesis of the destabilization of CAD 
leading to ACS: macrophages and neutrophils are 
implicated in the transformation of stable coronary 
artery plaques to unstable lesions and are found in 
high levels in the culprit lesions of patients with ACS 
(Takahiko N et al. 2002). They act by degrading the 
collagen layer that protects atheromas from erosion 
or abrupt rupture and in this setting, MPO has a 
pivotal role. In 1996, Biasucci et al. (Biasucci LM 
et al. 1996) observed that circulating neutrophils in 
patients with AMI and UA have a low MPO content, 
compared with those with chronic stable angina and 
variant angina. This is indicative of a signiﬁ  cant 
release of MPO from neutrophils related to their 
activation. Although MPO participates in the inﬂ  am-
matory process of ACS, neutrophil activation is 
apparently not induced by ischemia. In 2001, Zhang 
et al. (Zhang R et al. 2001), showed that blood and 
leukocyte myeloperoxidase activities were higher in 
patients with CAD than angiographically veriﬁ  ed 
normal controls, and that these increased activities 
were signiﬁ  cantly associated with presence of CAD 
( odds ratio, 11.9; 95% conﬁ  dence interval, 5.5–25.5). 
Results were independent of patient’s age, sex, 
hypertension, smoking, diabetes status, LDL con-
centration, leukocyte count, Framingham Global 
Risk Score. Buffon et al. (Buffon A et al. 2002) have 
enrolled 65 patients who underwent cardiac catheter-
ization with coronary sinus sampling and have 
observed that increases in MPO correlated with value 
of CRP in patients with ACS. The potential role of 
MPO as a marker for risk stratiﬁ  cation in patients 
with ACS was examined in recent studies. Brennan 
et al. (Brennan ML et al. 2003) have enrolled 604 
patients admitted to the ED with chest pain. They 
have investigated the correlation between risk of 
major cardiac events at 30 days and 6 months and 
increase in MPO concentration. The result was a 
progressive increase in odds ratios for major cardiac 
events with each quartile of MPO concentration. 
Even in the absence of myocardial necrosis, baseline 
measurements of MPO signiﬁ  cantly enhanced the 
identiﬁ  cation of patients at risk. Intriguingly, MPO 
was independent of both troponin and CRP levels. 
MPO predicted adverse outcome independently of 
sCD40L. This may imply that neutrophil activation 
represents an adjunct patho-physiological event in 
ACS that is distinctly different from platelet 
activation. In the CAPTURE trial (Baldus S et al. 
2003), MPO mass concentration was measured in 
1090 patients with diagnosis of ACS and the death 
and MI were determined at 6 months of follow up. 
The result was that MPO and the other markers 
studied (cTnT, soluble cd40L, CRP and vascular 
endothelial growth factor) were independent predic-
tors of adverse cardiac events. Using a cut-off 
of 350 μg/l for MPO in patients with ACS, adjusted 461
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hazard ratio was 2.25 (95% CI 1.32–3.82) and 
considering only patients with undectable 
cardiac troponin the hazard ratio was 
7.48  (95%  CI 1.98–28.29). Furthermore, Cavusoglu 
et al. (Cavusoglu E et al. 2007) have investigated the 
long-term prognostic signiﬁ  cance of baseline MPO 
levels in a well-characterized cohort of 193 men with 
ACS and have demonstrate that baseline MPO lev-
els independently predict MI at 2 years in patients 
with ACS. Similar data were also reported by 
Mocatta et al. (Mocatta TJ et al. 2007). Importantly 
Mocatta et al. also showed that MPO prediction of 
future events is independent from NT-proBNP and 
LVEF values. These ﬁ  ndings contrast with data from 
Apple et al. (Apple FS et al. 2007), who investigated 
correlation between multiple biomarkers and adverse 
outcomes rate in patients presenting to ED with 
symptoms suggestive of ACS. In this study MPO, 
sCD40L and MMP-9 levels were not independently 
associated with death, whereas patients with 
increased levels of PIGF, NT-proBNP, CRP, cTnI or 
decreased eGFR had higher mortality rate than 
patients with normal value of these biomarkers. Of 
note, however, patients with both cTnI and MPO 
raised levels had a mortality rate close to 40%.
In summary, observations from studies that have 
investigated MPO activity, demonstrated MPO is 
more than a marker of oxidative stress and not only 
a marker of plaque instability. These patho-physi-
ological characteristics are very interesting but 
more studies are needed to assess sensitivity and 




Pregnancy-associated plasma protein (PAPP-A) is a 
high molecular mass (∼200 kDa) glycoprotein typi-
cally measured during pregnancy for screening of 
Down syndrome (Wald  NJ et al. 1996). Physiologically, 
PAPP-A circulates in a hetero-tetrameric complex 
consisting of two PAPP-A subunits covalently bound 
with two subunits of the pro-form of eosinophil major 
basic protein (proMBP), its endogenous inhibitor 
(Oxvig C et al. 1993). PAPP-A has also been impli-
cated in coronary plaque disruption (Lawrence JB 
et al. 1999). Preliminary results provide evidence that 
circulating PAPP-A during ACS is different from 
PAPP-A isolated from pregnancy sera (Quin QP et al. 
2002). It is released during atherosclerotic plaque 
disruption in a homodimeric active form, uncomplexed 
with the inhibitor proform of eosinophil major basic 
protein (proMBP) contrary to the form present during 
pregnancy. Bayes-Genis et al. found abundant 
PAPP-A expression in unstable plaques but not in 
stable plaques from patients died of sudden cardiac 
death, mostly in the inﬂ  ammatory shoulder region. 
They also described increased PAPP-A concentrations 
in the serum of patients with both UA and AMI, with 
PAPP-A levels  10 mIU/l identifying ACS patients 
with a sensitivity of 89% and a speciﬁ  city of 81% 
(Bayes-Genis A et al. 2001).
PAPP-A blood levels seem to be an independent 
predictor of ischemic cardiac events and indicative 
of revascularization in patients with suspected MI 
but negative troponin: Lund J et al. found that PAPP-
A plasma levels  2.9 mUI/l were associated with a 
risk of MI, death or revascularization 4.6-fold higher 
vs PAPP-A plasma levels  2.9 mUI/l (Lund J et al. 
2003). Similar results were obtained by Heeschen 
et al. (Heeschen C et al. 2003b). They demonstrated 
the role of PAPP-A as independent marker of future 
cardiac events in ACS patients. However the overall 
correlation of PAPP-A with Catnip and CK-MB 
concentrations appears to be weak, indicating that 
increased PAPP-A cannot be attributed to myocardial 
necrosis. A signiﬁ  cant association between PAPP-A 
and CRP concentration was shown in the ﬁ  rst stud-
ies, but was not conﬁ  rmed by subsequent papers. 
(Heeschen C et al. 2003b; Oxvig C et al. 1993).
Although preliminary studies suggest that 
PAPP-A may be useful to evaluate patients with ACS, 
additional investigations will be necessary for better 
acceptance of PAPP-A as an independent biomarker 
for cardiovascular risk in ACS. It is difﬁ  cult to mea-
sure PAPP-A present in atherosclerotic plaques by 
immunoassays because they are designed to detect 
PAPP-A present in pregnancy sera. The kinetics of 
PAPP-A release and the corresponding optimal sam-
pling protocols in ACS remain to be determined 
(Quin QP et al. 2002). Because preliminary ﬁ  ndings 
showed that serum PAPP-A concentrations sensi-
tively reﬂ  ect changes in renal function and correlate 
with serum creatinine, the possible inﬂ  uence of renal 
function on PAPP-A concentrations should be also 
clariﬁ  ed (Fialova L et al. 2004).
Metalloproteinase-9
Metalloproteinases (MMPs) are a class of 24 
endopeptidases that are physiologic regulators of 
the extracellular matrix (Visse R and Nagase H, 
2003). They are an expanding group of proteolytic 462
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enzymes that participate in numerous physiological 
and pathological processes including embryogenesis, 
connective tissue turn-over, healing, angiogenesis 
(Dabek J et al. 2007). Disturbances in matrix 
activity are observed in carcinogenesis, in some 
degenerative processes, and in inﬂ  ammatory con-
ditions, including atherogenesis. The role of matrix 
in the pathology of the cardiovascular system 
seems to be particularly important in two pro-
cesses: (1) atherosclerotic plaque development and 
rupture (leading to an acute coronary event) and 
(2) post-infarction remodelling of myocardium, 
leading to heart failure. Human atherosclerotic 
lesions overexpress human interstitial collage-
nases, members of the matrix metalloproteinase 
family (Dollery CM and Libby P, 2006). Inﬂ  am-
matory stimuli augment the production of the 
interstitial collagenases MMP-1, MMP-13, MMP-
8 from several cell types found in atherosclerotic 
plaques. Human atherosclerotic plaque also con-
tains elevated levels of MMP-9 active form, an 
enzyme with gelatinolytic activity that can con-
tinue the catabolism of collagen cleaved by inter-
stitial collagenases (Galis Z et al. 1994a). 
Inﬂ  ammatory mediators regulate this enzyme, 
which can also degrade elastin ( Galis Z et al. 
1994b). Recently, Fiotti et al. (Fiotti N et al. 2007) 
have studied patients with stable angina and 
patients with ACS undergoing PCI and have 
assessed MMP-2, MMP-9 and TIMP-1 expres-
sions. They have found that MMP-9, but not 
TIMP-1 or MMP-2 expression is increased in 
plaques causing ACS. MMP-9 is localized in the 
plaque shoulder, the thinner area prone to rupture. 
So MMP-9 may be the most promising, among 
MMP, as marker.
Kai H et al. ( Kai H et al. 1998) measured MMP-9 
concentration in ACS patients and stable angina 
patients compared with healthy controls. Patients 
with stable angina had a MMP-9 concentration 
similar to healthy controls; all patients with UA 
had elevated levels of MMP-9 at entry, that 
decreased gradually during hospitalization. 
Intriguing data from Inokubo’s group (Inokubo Y 
et al. 2001) showed a substantial gradient of both 
MMP-9 and tissue inhibitor of metalloproteinases 
1 (TIMP-1) across the coronary sinus suggesting 
a local release/production of these molecules.
The potential role of MMP-9 as a marker for 
risk stratification of patients with ACS was 
examined by Blankenberg et al. (Blankenberg S 
et al. 2003): they studied 1127 patients with 
stable (n = 795) and unstable (n = 332) angina 
and found that MMP-9 values were related to 
future cardiovascular death. Its prognostic value 
was also maintained after correction for CRP, 
ﬁ  brinogen, IL-6, IL-18. Indeed, MMP production 
seemed to be important for reparative process of 
cardiac tissue after injury, although previous data 
showed that transgenic animals susceptible to 
ventricular rupture are protected by deletion of 
MMP-9 gene ( Heymas S et al. 1999).
Brieﬂ  y, preliminary studies suggest that MMP-9 
may be of value in evaluating ACS patients but 
additional investigations will be necessary for 
better acceptance of MMP-9 commercialization 
and clinical application.
Markers of Ischemia-Necrosis
Fatty acid binding proteins (FABPs)
FABPs are low-molecular-mass proteins that are 
abundant in the cytoplasm of tissues having active 
fatty acid metabolism, including the heart, striated 
muscle, liver and intestine. FABPs are the major 
vehicle for cytosolic transport of long-chain unester-
iﬁ  ed fatty acids (Ockner RK et al. 1972) . Myocardium 
and skeletal muscle contain the same isoform of 
FABP, termed heart-type FABP (H-FABP), but the 
content of this protein in skeletal muscle is only 
10% –30% of that found in cardiac muscle. H-FABP 
concentration in healthy donors is relatively low 
(2–6 μg/l) and it has a very good tissue/plasma ratio. 
Age, sex and circadian rhythm signiﬁ  cantly inﬂ  u-
ence H-FABP reference value. Probably because of 
their larger muscle mass, men have higher plasma 
H-FABP concentration than women. Because 
H-FABP has predominantly a renal clearance and 
renal function decreases with age, plasma H-FABP 
may increase with age (Tsuji R et al. 1993).
H-FABP appears in blood soon after the onset 
of infarction, so it has been proposed as an early 
marker for the MI diagnosis (Kleine AH et al. 
1992). Its plasma concentration increase within 
2–3 h after MI and return to the normal range 
within 12–24 h in individuals without renal 
impairment.
In general, H-FABP was found to perform better 
than or similar to myoglobin in diagnosis of ACS 
(Okamoto F et al. 2000), probably due to the higher 
cardiac tissue content of H-FABP compared with 
myoglobin. Seino et al. (Seino Y et al. 2004) 
compared blood rapid test for H-FABP with rapid 463
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cTnT test regarding diagnostic accuracy in cardiac 
ischemia: rapid H-FABP assay seemed to effec-
tively exclude non-AMI patients within 3 h of 
onset. Therefore, H-FABP may be useful in the 
diagnostic assessment of ACS patients in ED, in 
combination with troponin, along with the electro-
cardiographic and clinical evaluation. Because of 
different amounts of H-FABP and myoglobin in 
myocardial and skeletal muscle tissue a low mio-
globin/H-FABP ratio might have myocardial 
speciﬁ  city. In fact, myoglobin/H-FABP ratio was 
found to be low (values in the range of 2–10) in 
plasma from patients with myocardial injury and 
high (values in the range of 20–70) in patients with 
skeletal muscle damage (Van Nieuwenhoven FA 
et al. 1995). However, strategies to improve detec-
tion of myocardial injury by calculating myoglo-
bin/H-FABP ratio haven’t yielded a clear advantage 
over the measurement of H-FABP alone. Nakata 
et al. have shown that H-FABP has greater diag-
nostic value and sensitivity than cTnT, CKMB and 
myoglobin in patients with suspected ACS within 
6 h from acute chest pain onset (Nakata T et al. 
2003) and an early or sustained elevation in H-
FABP could indicate unfavourable clinical out-
come (Suzuki M et al. 2005), as conﬁ  rmed by 
Nagahara (Nagahara D et al. 2006), too, who found 
a higher positive predictive value (84%–91%), a 
higher sensitivity (75%–77%) and a better negative 
predictive value (nearly 40%) for H-FABP vs cTnT, 
CK-MB and myoglobin. However, in these studies 
low sensitivity troponins were used, therefore 
reducing cTnT sensitivity for ACS. In a recent 
study O’Donoghue et al. (O’Donoghue et al. 
2006), have evaluated H-FABP, Troponin and BNP 
levels of 2287 patients with ACS from the OPUS-
TIMI 16 trial and have found that elevation of 
H-FABP is associated with an increased risk of 
death and major cardiac events at 10 months 
of follow up, independently from other established 
clinical risk predictors and biomarkers. Indeed, it 
provides incremental prognostic information 
regardless of baseline troponin or BNP status.
Because H-FABP rapidly return to the normal 
range within 24 h after AMI, it can be also used to 
assess a recurrent infarction within 10 h after ﬁ  rst 
AMI, possibly missed by CK-MB, cTnT and cTnI 
evaluation because plasma concentration of these 
markers returns more slowly to reference values. 
H-FABP has a renal clearence, therefore impaired 
renal function potentially impact its clinical utility; 
however, data from de Groot et al. (de Groot et al. 
1999) indicate that H-FABP, after correction for 
estimated renal function, can be applied successfully 
for infarct size estimation.
The rapid release of H-FABP can also be used 
for the detection of successful coronary reperfusion 
in patients with AMI (Suzuki M et al. 2005). Both 
plasma H-FABP and myoglobin levels were found 
to increase sharply after successful reperfusion, 
slowly after failed reperfusion.
Suzuki and coll. (Suzuki M et al. 2005) have 
recently showed that a positive H-FABP test is an 
independent predictor of adverse events within 
30 days in patients with ACS. Increased plasma 
H-FABP concentration signiﬁ  cantly correlate with 
cardiac events and mortality (Ishii J et al. 2003). 
Although H-FABP is generally considered a 
marker of myocardial necrosis, a recent study has 
indicated its additional potential utility as a marker 
of ischemia, also in absence of myocardial necrosis, 
therefore it could be useful for early identiﬁ  cation 
of ACS in patients with chest pain of uncertain 
origin (Tambara K et al. 2004).
Free fatty acids unbound
to albumin (FFAu)
Free fatty acids unbound to albumin (FFAu) were 
also evaluated for early identiﬁ  cation of cardiac 
ischemia. FFAs are localized in the cytoplasm, 
bound to fatty acid binding protein (FABP) and 
represent the primary metabolic sources for 
myocardium. During hypoxia and ischemia, 
elevated blood cathecolamines increase FFAu 
concentration through adipose lipolyses activation. 
Increased non-esteriﬁ  ed fatty acids/FFA levels have 
damaging effects on heart tissue and have been 
associated with an increased incidence of ventricular 
dysrhytmias and death in patients with AMI.
Several investigators have preliminarily evaluated 
the sensitivity of this marker on admission to emer-
gency room and have shown that FFAu elevation 
occurs before other, more traditional, markers of 
cardiac necrosis (Adams JE et al. 2002). In the TIMI 
II trial FFAu concentration were measured in 
458 patients on admission and 50 min, 5 h and 8 h 
after the initiation of tissue Plasminogen Activator 
(tPA) treatment (Kleinfeld AM et al. 2002). Sensitiv-
ity of FFA was 91% at admission and 98% 50 min 
after tPA (cut-off 5 nmol/l); speciﬁ  city, compared 
with healthy individuals and patients with non car-
diovascular disease, was 93%. FFAu were increased 
in 100% of MI patients on admission, whereas only 464
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22% of these patients had increased cTnI at 
presentation, indicative of earlier appearance of this 
analyte in the circulation before traditional markers 
of myocite necrosis (Apple FS et al. 2005).
FFAu have also been studied for risk stratiﬁ  cation 
of ischemic heart disease (IHD). In the Paris 
Prospective Study I, increased plasma FFAu con-
centration were found to be an independent risk 
factor of sudden death, but not of fatal MI in a cohort 
of men without known ischemic cardiac disease 
(Jouven X et al. 2001). Pirro et al. (Pirro M et al. 
2002) studied the relationship between circulating 
FFAu concentration and risk of IHD in 2130 men 
with insulin resistance syndrome and without IHD 
at enrollment. During a 5-year follow-up, 114 of 
these individuals developed IHD. After adjustment 
for nonlipid risk factors, increased circulating FFAu 
levels conferred a 2-fold increase of IHD risk (odds 
ratio, 2.1; P = 0.05). However, after adjustment for 
triglyceride concentrations, HDL-cholesterol, small 
and dense LDL, apolipoprotein B, and fasting 
plasma insulin, the relationship between plasma 
FFAu concentration and IHD development didn’t 
achieve statistical signiﬁ  cance.
Pilz et al. (Pilz S et al. 2006) studied 3315 
Caucasians from LURIC study to elucidate the 
relationship between FFAu and mortality in 
subjects undergoing coronary angiography at a 
median follow up of 5.38 years. This follow-up 
study demonstrated that high levels of FFAu may 
predict total and cardiovascular mortality and its 
predictive value for all-cause and cardiovascular 
mortality remains stable even after multivariable 
(CRP, creatinine, homocysteine, NT-proBNP) 
adjustments. These support the idea of a direct 
involvement of FFAu in atherosclerotic patho-
physiological process.
In conclusion, current data, although limited, 
suggest that monitoring FFAu concentrations in 
patients presenting with ischemia symptoms may 
provide an early indication of cardiac ischemia. 
Additional studies are needed to fully evaluate the 
true potential of this biomarker.
Ischemia modiﬁ  ed albumin (IMA)
Ischemia modiﬁ  ed albumin (IMA), measured by 
the albumin cobalt binding test (ACB), has been 
shown to be a marker of myocardial ischemia. 
A multicenter study (Christenson RH et al. 2001), 
involving 224 patients, who arrived at the ED within 
3 h after symptoms onset, examined the ability of 
the ACB test to predict a positive or negative cTnI 
result within 6–24 h after presentation. All patients 
had a negative cTnI result at presentation. At the 
optimum cut-off for the ACB test, sensitivity and 
speciﬁ  city were 70% and 80%, respectively, with 
a negative predictive value of 96%. In the study by 
Bhagavan et al. (Baghavan NV et al. 2003) the 
sensitivity and speciﬁ  city for myocardial ischemia 
were 88% and 94%, respectively, and the positive 
and negative predictive values were 92% and 91%. 
Another study (Sinha MK et al. 2004) evaluated 
IMA in conjunction with EKG results and cTnT 
concentrations ( 0.05 μg/L) in 208 patients 
presenting to the ED within 3 h of acute chest pain. 
In the whole patient group, sensitivity of IMA at 
presentation for an ischemic origin of chest pain 
was 82%, speciﬁ  city was 46%, the negative predic-
tive value was 59%, and the positive predictive 
value was 72%. IMA, EKG, and cTnT combined 
identiﬁ  ed 95% of patients whose chest pain was 
attributable to ischemic heart disease.
The positive predictive value of the ACB assay 
seems to be too low for use in ruling in ischemia. 
At present, whether patients with negative EKG 
results and necrosis markers, i.e. cardiac troponins, 
and a positive IMA result might beneﬁ  t from early 
triage and intervention according to stratiﬁ  ed pre-
test probabilities is not known. In clinical practice, 
this lack of information can potentially lead to 
overtreatment of low-risk patients with a positive 
result.
Recent ﬁ  ndings suggest that IMA may be also 
useful in risk stratiﬁ  cation of emergency chest pain 
patient (Pollack CV et al. 2003). Peacock et al. 
(Peacock et  al. 2006) have performed a 
meta-analysis of IMA in ACS risk stratiﬁ  cation. In 
the presence of a triple negative prediction test 
(nondiagnostic electrocardiogram, negative 
troponin, and negative IMA) they found that 
sensitivity and negative predictive value for ACS 
were 94.4% and 97.1% and, for long-term out-
comes, were 89.2% and 94.5%, respectively. 
However, in the short term, in patients presenting 
with chest pain who have not yet experienced a 
serious cardiac event, IMA is a poor predictor of 
serious cardiac outcomes (death, myocardial 
infarction, congestive heart failure, serious 
arrhythmia, or refractory ischemic cardiac pain) 
(Worster A et al. 2005).
IMA appears to be indicative of oxidative stress 
and, therefore, might not be speciﬁ  c for cardiac isch-
emia. Increased IMA values are also found in patients 465
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with cancer, infections, end-stage renal disease, liver 
disease, and brain ischemia (Wu AH, 2003).
In summary, many questions remain unanswered 
regarding IMA and the ACB test. The highest 
expected beneﬁ  t of the test would be to rule out 
ACS in low to moderate pre-test probability 
conditions with negative myocardial necrosis mark-
ers and a negative EKG. However, the test seems 
to have limited speciﬁ  city, with many false posi-
tives. Additional information, including a better 
understanding of IMA kinetics in the ﬁ  rst hours 
after ACS and an optimum diagnostic cut-off value 
assessment, is needed for clinical validation of this 
new assay.
Conclusions
Increasing evidence suggests that the use of 
biomarkers, reﬂ  ecting distinct pathophysiological 
features such as oxidative stress, vascular inﬂ  am-
mation, platelet activation, plaque destabilization 
and rupture along with more sensitive biomarkers 
of necrosis, may improve the traditional diagnostic 
and risk stratiﬁ  cation approach in order to apply 
tailored treatment. However, no available biomarker 
offers ideal properties such as very early raise, very 
high sensitivity and speciﬁ  city, easy and cheap 
assay. These observations suggest a multi-marker 
strategy, employing patho-biologically different 
biomarkers, that might help signiﬁ  cantly in the 
identiﬁ  cation of the “vulnerable” patient at risk for 
CHD, as suggested by a recent National Institutes 
of Health (NIH) panel (Morrow DA et al. 2003). 
A multi-marker strategy, based on the use of a 
combination of two or more markers to enable the 
detection of myocardial infarction in patients who 
seek care early and late after symptom onset, could 
consent an early diagnosis and facilitate identiﬁ  ca-
tion of patients standed for aggressive interventions. 
However there is no evidence that a strategy based 
on measurement of more than two markers (besides 
troponin and CRP or natriuretic peptides) might 
improve diagnostic and prognostic power of a two 
markers strategy. So far, indeed, consistent and 
reliable data on diagnostic and prognostic value of 
these markers are available only for Troponin, BNP 
and CRP. Further studies are need to establish the 
role of new biomarkers and to cross boundaries 
from research to clinical practice.
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